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ABSTRACT 
Objective: To re-appraise clinicians 
that huge ovarian lesions with 
features of malignancies may still be 
benign and that late presentation is a 
problem in genital cancer management 
that should be addressed. 
Subject, material and method: A 
case report of a huge benign granulosa 
cell tumour in a postmenopausal woman 
is presented. 
Results: She presented as a case of 
a huge right ovarian tumour with 
weight loss, respiratory and abdominal 
discomfort one year after initial 
diagnosis was made because of fear 
of surgery. She had laparotomy, total 
abdominal hysterectomy and bilateral 
salpingoophorectomy. Histology revealed 
granulosa cell tumour of the benign 
type. 
Conclusion: Huge ovarian tumours in 
the elderly could be benign. In the 
absence of proper screening technique 
for ovarian cancers, laparotomy for 
histological purposes is required. Health 
education and proper counselling is 
imperative to reduce delays of 
patients to hospitals. 
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In the developing graafian 
follicle, the central core of granulosa 
cells is surrounded by the theca cells 
derived from the ovarian stroma.  After 
ovulation, some granulosa cells 
remain in the corpus luteum, and 
remain separate from a layer of theca 
cells of varying thickness.  In rare 
cases, approximately one fifth as 
frequently, Sertoli cells similar to those 
supporting cells of the testis, are also 
found in the ovary, leading to a 
Sertoli-Leydig cell tumour (otherwise 
called “androblastoma”), which may be 
virilising, endocrinologically inactive or 
oestrogenic.  In the tumours derived 
from these elements, the proportion of 
these cell types which produce 
oestrogen (or occasionally androgen) 
is highest in granulosa cell tumour, 
and relatively rare in the other 
tumours. 
PRESENTATION 
The majority are stage I tumours 
and have a relatively good prognosis.  
Granulosa cell tumours are the most 
common and may be oestrogen producing 
leading to precocious puberty, amenorrhoea, 
peri-menopausal bleeding and virilising 
symptoms1. Significant clinical changes 
of hyperestrogenism are evident in 
less than 15% of patients at presentation.  
Some are associated with ovarian 
hyperstimulation following infertility 
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treatment, and there is also an 
association with the Peutz-jeghers 
syndrome1. The prognosis of 
granulosa cell tumours is generally 
good, which may reflect their early 
stage and good differentiation. It 
should be noted that there is small 
risk of delayed relapse as late as 25 
years after initial presentation so long 
term follow up is advised2,3. Serum 
tumour markers include oestradiol, 
FSH, LH and serum inhibins4. 
PATHOLOGY 
It is recognized that this group of 
tumours is rare and the diagnosis is 
frequently difficult.  It is therefore 
strongly recommended that tumours 
in this category be subject to detailed 
review by an expert gynaecologic 
pathologist.  Furthermore, additional 
slides and/or tissue blocks should be 
retained for future molecular analysis. 
TREATMENT 
In younger pre-menopausal 
women with localised disease, there 
may be a role for conservative fertility-
sparing surgery. This would include at a 
minimum, removal of the affected 
ovary and extended surgical staging. 
If fertility is not an issue, then a 
complete hysterectomy with bilateral 
salpingoophorectomy and omentectomy 
are appropriate.  In those women with 
more advanced disease, surgical 
debulking adopting the general 
principles applied in epithelial ovarian 
cancer should be considered5. 
CHEMOTHERAPY 
There is no role for adjuvant 
chemotherapy on a routine basis. For 
those women with macroscopic or 
microscopic residual disease (i.e. 
Stage II – IV) cisplatinum based 
chemotherapy has been the most 
commonly utilized either combined with 
vinblastine and bleomycin or adriamycin 
and cyclophosphamide. Most authors 
would now recommend the use of 
bleomycin, eptoposide and platinum 
(BEP) for a minimum of 3-4 cycles6,7 
There is a current Gynaecologic 
oncology group {GOG} trial (GOG 
#187) that is seeking to identify the 
role of taxanes in the management of 
these women8.  Carboplatin and 
paclitaxel may become established as 
an alternative first line therapy.9 
A more frequent clinical setting 
than a primary diagnosis of advanced 
granulosa cell tumour is that of a 
woman presenting with recurrent 
granulosa cell tumour.  In this 
situation, cytoreductive surgery should 
be the primary approach with systemic 
chemotherapy as above for residual 
disease.  If the recurrent disease is 
not resectable at the time of 
presentation, one may consider 2-3 
cycles of BEP (or carboplatin and 
paclitaxel) pre-operatively and follow 
interval cytoreductive surgery with 
another 2-3 cycles.7,9 
The need for additional clinical 
trials of sufficient size to provide good 
evidence of efficacy is required in this 
area. Given the rarity of these 
tumours, international collaboration is 
needed to achieve this aim. Markers 
used for diagnoses and monitoring of 
granulosa cell tumours include serum 
inhibin, mullerian inhibiting substance, 
oestrogen, progesterone, luteinising 
and follicle stimulating hormones. 
None of these has become 
established in routine use. 
CASE REPORT 
Mrs E.V, a 61 year old para 6+0 
who was 10 years postmenopausal 
presented at the gynaecological clinic 
of the Baptist Medical Centre in March 
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of 2004 with a history of abdominal 
swelling of 12 months duration. She 
was a known diabetic on oral 
hypoglycaemic agent. Swelling was 
first noticed as a suprapubic mass 
when she presented for her routine 
check up in the medical outpatient a 
year ago. Ultrasound scan done then 
revealed a complex right ovarian cyst. 
She was counselled for surgery but 
defaulted. Abdominal swelling grew 
rapidly in the last 3 months and was 
associated with mild respiratory and 
abdominal discomfort necessitating 
her presentation in hospital. There 
was associated weight loss. Bowel 
motion was once daily and stools 
were watery. There was no abdominal 
pain but appetite was reduced. She 
neither had cough nor chest pain. 
There was no bleeding or discharge 
per vaginam. Menarche was at 15 
years of age and there was no past 
history of oral contraceptive use or 
oestrogen preparations. There has 
been no family history of breast, 
ovarian or colonic cancers. She had 6 
normal deliveries from 1963-1984 and 
all the children were breastfed. She 
was a trader married to a retiree in a 
monogamous setting. She neither 
smoked cigarettes nor drank alcohol. 
Late presentation was due to fear of 
surgery. 
On examination, she was 
chronically ill looking, slightly pale, her 
chest was clinically clear and her 
cardiovascular system was stable. 
Abdominal examination revealed a 
uniformly enlarged mass compatible 
with a 36 week pregnant uterus. It 
was firm to hard, not mobile, irregular 
and non tender. There was associated 
ascites. Vagina examination showed 
oedematous vulva and vagina, healthy 
cervix and the uterus could not be 
delineated. The pouch of Douglas was 
free. The rectal mucosa was free. A 
diagnosis of ovarian cancer was 
made. Her packed cell volume was 
34% She had a normal electrolyte and 
urea level, chest x-ray and tested 
negative for HIV 1and 11. Fasting 
blood sugar was 167mg/dl. Liver 
function test was also normal. 
Ultrasound scan revealed a huge 
multiseptate cystic intraabdominal 
mass with a thick wall. The uterus was 
not visualized. She had a right 
ovariectomy, total abdominal hysterectomy 
and left salpingoophorectomy after 
stabilization of her glucose level. 
Findings at surgery were mild ascitic 
peritoneal cavity, huge right ovarian 
cyst measuring 37cm/29cm as in 
figure 1a, weighing 8.3 kg with a thick 
smooth wall without excrescences on 
surface. The cyst contained 6liters of 
serosanguinous fluid. The left ovary 
was atretic without evidence of 
malignancy. The uterus was small but 
normal. The bowels were adherent to 
the mass on the posterior surface and 
were separated. The abdominal 
organs were normal. Ascitic fluid did 
not show malignancy. The surgical 
specimen showed tumour composed 
of sheets and trabeculae of granulosa 
cells. Small follicles and Call-Exner 
bodies interspersed in the sheets and 
trabeculae of granulosa cells.The final 
diagnosis was that of granulosa cell 
tumor. She had an uneventful 
postoperative period and was 
discharged home to be seen at the 
gynaecology clinic. She was clinically 
stable when she was seen 3 weeks 
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Figure 1a: Macroscopic view and     Figure 1b: Cut section of granulosa tumour. 
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DISCUSSION 
Granulosa cell tumours belong to 
the sex cord stromal group and 
include tumours made up of granulosa 
cells, theca cells and fibroblast in 
varying degrees and combinations. It 
accounts for approximately 2% of all 
ovarian tumours and can be divided 
into adult type (95%) and juvenile type 
(5%) based on histologic findings. 
These tumours have a propensity for 
indolent growth and late recurrence; 
they may even recur 2 – 3 decades 
after initial treatment2,3.  Both subtypes 
are oestrogen producing and this 
could be the reason for early 
diagnoses. Mrs E.V presented as a 
result of increasing abdominal 
swelling and respiratory distress. 
There was no history of 
oestrogenisation effects such as post 
menopausal bleeding. Most patients 
will present with one or a combination 
of symptoms such as vaginal 
bleeding, abdominal distension and/or 
abdominal pain10. However, despite 
the rather large lesion at diagnosis, 
80%-90% of patient will present with 
stage 1 disease and it is usually 
unilateral in 95% of cases as in this 
patient10. 
Late presentation of patients to 
hospitals especially in cases due to 
genital malignancies is a common 
feature in our environment. Various 
reasons attributable to this range from 
poverty, ignorance, superstitious 
beliefs and fear of surgery. Mrs E.V 
delayed for 1 year prior to 
presentation because of fear of death 
from resultant surgery. If this were a 
malignant lesion, she would have 
either presented dead or terminally ill. 
Treatment of postmenopausal 
women is total abdominal 
hysterectomy and bilateral salpingo-
oophorectomy while salpingo-oophorectomy 
may be acceptable in younger patient 
wishing to preserve fertility. In 
developing countries where tumour 
markers such as inhibin and calretinin 
are not available, appropriate staging 
laparotomy and tissue biopsy for 
histology should be carried out. 
However these markers have a 
limitation of being positive in other 
ovarian lesions. Diagnosis of ovarian 
cancer is made on the basis of 
clinical, radiological, biochemical and 
surgical diagnosis. Definitive diagnosis 
is made at laparotomy with histological 
confirmation. 
CA-125 protein is the most 
valuable tumour marker in the field of 
ovarian cancer11.  This marker is 
produced by most ovarian cancers. It 
is released in the blood during 
pregnancy and is produced in other 
conditions such as endometriosis, 
fibroids and diverticulitis. It is useful in 
monitoring therapy. Since frequent 
late recurrence is hallmark of 
granulosa cell tumour, long time follow 
up should be emphasized. 
In conclusion, huge ovarian 
tumours in the elderly could be 
benign. Granulosa cell tumours have 
the propensity of becoming recurrent 
and malignant even when this rarely 
occurs. In the absence of proper 
screening technique for ovarian 
cancers, laparotomy for histological 
purpose is required. Increase in socio-
economic status, proper health education 
and counselling is imperative if we are 
to reduce delays in presentation of 
patients to hospitals in our setting. 
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